APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Vaccine Contract Manufacturing

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Human Vaccine Contract Manufacturing Market Analysis and Forecast 2026-2032

3 May 2026201 pages

Choose your research edition.

Industry ResearchHuman Vaccine Contract Manufacturing Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Vaccine Contract Manufacturing Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Human Vaccine Contract Manufacturing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Vaccine Contract Manufacturing Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Vaccine Contract Manufacturing Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Human Vaccine Contract Manufacturing market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Human Vaccine Contract Manufacturing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Human Vaccine Contract Manufacturing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Human Vaccine Contract Manufacturing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Human Vaccine Contract Manufacturing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Human Vaccine Contract Manufacturing include Lonza, Fujifilm Diosynth Biotechnologies U.S.A., Inc., Ajinomoto Althea, Inc., Merck KgaA, Cytovance Biologics, Catalent, Inc., IDT Biologika GmbH, Albany Molecular Research, Inc. and PRA Health Sciences, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Human Vaccine Contract Manufacturing, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Human Vaccine Contract Manufacturing, also provides the revenue of main regions and countries. Of the upcoming market potential for Human Vaccine Contract Manufacturing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human Vaccine Contract Manufacturing revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Human Vaccine Contract Manufacturing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Human Vaccine Contract Manufacturing revenue, projected growth trends, production technology, application and end-user industry.

Human Vaccine Contract Manufacturing Segment by Company

Lonza

Fujifilm Diosynth Biotechnologies U.S.A., Inc.

Ajinomoto Althea, Inc.

Merck KgaA

Cytovance Biologics

Catalent, Inc.

IDT Biologika GmbH

Albany Molecular Research, Inc.

PRA Health Sciences

ICON plc.

Pharmaceutical Product Development, LLC

Cobra Bio

Paragon Bioservices, Inc.

Emergent BioSolutions Inc.

CSL Limited

BioNTech SE

Wuxi Biologics

Samsung Biologics

Boehringer Ingelheim

Novavax, Inc.

Human Vaccine Contract Manufacturing Segment by Type

Attenuated

Inactivated

Subunit-based

Toxoid-based

DNA-based

Human Vaccine Contract Manufacturing Segment by Application

Downstream

Upstream

Human Vaccine Contract Manufacturing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Vaccine Contract Manufacturing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Vaccine Contract Manufacturing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Vaccine Contract Manufacturing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Human Vaccine Contract Manufacturing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Human Vaccine Contract Manufacturing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Vaccine Contract Manufacturing revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Attenuated Major Player Table 3. Inactivated Major Player Table 4. Subunit-based Major Player Table 5. Toxoid-based Major Player Table 6. DNA-based Major Player Table 7. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Downstream Major Player Table 9. Upstream Major Player Table 10. Human Vaccine Contract Manufacturing Industry Trends Table 11. Human Vaccine Contract Manufacturing Industry Drivers Table 12. Human Vaccine Contract Manufacturing Industry Opportunities and Challenges Table 13. Human Vaccine Contract Manufacturing Industry Restraints Table 14. Global Human Vaccine Contract Manufacturing Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Human Vaccine Contract Manufacturing Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Human Vaccine Contract Manufacturing Market Share by Region (2021-2026) Table 17. Global Human Vaccine Contract Manufacturing Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Human Vaccine Contract Manufacturing Market Share by Region (2027-2032) Table 19. Global Human Vaccine Contract Manufacturing Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Human Vaccine Contract Manufacturing Revenue Market Share by Players (2021-2026) Table 21. Global Human Vaccine Contract Manufacturing Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Human Vaccine Contract Manufacturing Key Players Headquarters & Area Served Table 23. Global Human Vaccine Contract Manufacturing Players, Product Type & Application Table 24. Global Human Vaccine Contract Manufacturing Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Human Vaccine Contract Manufacturing by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Human Vaccine Contract Manufacturing Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Human Vaccine Contract Manufacturing Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Human Vaccine Contract Manufacturing Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Human Vaccine Contract Manufacturing Revenue Market Share by Type (2021-2026) Table 31. Global Human Vaccine Contract Manufacturing Revenue Market Share by Type (2027-2032) Table 32. Global Human Vaccine Contract Manufacturing Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Human Vaccine Contract Manufacturing Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Human Vaccine Contract Manufacturing Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Human Vaccine Contract Manufacturing Revenue Market Share by Application (2021-2026) Table 36. Global Human Vaccine Contract Manufacturing Revenue Market Share by Application (2027-2032) Table 37. Lonza Company Information Table 38. Lonza Business Overview Table 39. Lonza Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Lonza Human Vaccine Contract Manufacturing Product Portfolio Table 41. Lonza Recent Development Table 42. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Company Information Table 43. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Business Overview Table 44. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 46. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Development Table 47. Ajinomoto Althea, Inc. Company Information Table 48. Ajinomoto Althea, Inc. Business Overview Table 49. Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 51. Ajinomoto Althea, Inc. Recent Development Table 52. Merck KgaA Company Information Table 53. Merck KgaA Business Overview Table 54. Merck KgaA Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Merck KgaA Human Vaccine Contract Manufacturing Product Portfolio Table 56. Merck KgaA Recent Development Table 57. Cytovance Biologics Company Information Table 58. Cytovance Biologics Business Overview Table 59. Cytovance Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Cytovance Biologics Human Vaccine Contract Manufacturing Product Portfolio Table 61. Cytovance Biologics Recent Development Table 62. Catalent, Inc. Company Information Table 63. Catalent, Inc. Business Overview Table 64. Catalent, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Catalent, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 66. Catalent, Inc. Recent Development Table 67. IDT Biologika GmbH Company Information Table 68. IDT Biologika GmbH Business Overview Table 69. IDT Biologika GmbH Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. IDT Biologika GmbH Human Vaccine Contract Manufacturing Product Portfolio Table 71. IDT Biologika GmbH Recent Development Table 72. Albany Molecular Research, Inc. Company Information Table 73. Albany Molecular Research, Inc. Business Overview Table 74. Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 76. Albany Molecular Research, Inc. Recent Development Table 77. PRA Health Sciences Company Information Table 78. PRA Health Sciences Business Overview Table 79. PRA Health Sciences Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. PRA Health Sciences Human Vaccine Contract Manufacturing Product Portfolio Table 81. PRA Health Sciences Recent Development Table 82. ICON plc. Company Information Table 83. ICON plc. Business Overview Table 84. ICON plc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. ICON plc. Human Vaccine Contract Manufacturing Product Portfolio Table 86. ICON plc. Recent Development Table 87. Pharmaceutical Product Development, LLC Company Information Table 88. Pharmaceutical Product Development, LLC Business Overview Table 89. Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product Portfolio Table 91. Pharmaceutical Product Development, LLC Recent Development Table 92. Cobra Bio Company Information Table 93. Cobra Bio Business Overview Table 94. Cobra Bio Human Vaccine Contract Manufacturing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Cobra Bio Human Vaccine Contract Manufacturing Product Portfolio Table 96. Cobra Bio Recent Development Table 97. Paragon Bioservices, Inc. Company Information Table 98. Paragon Bioservices, Inc. Business Overview Table 99. Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 101. Paragon Bioservices, Inc. Recent Development Table 102. Emergent BioSolutions Inc. Company Information Table 103. Emergent BioSolutions Inc. Business Overview Table 104. Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 106. Emergent BioSolutions Inc. Recent Development Table 107. CSL Limited Company Information Table 108. CSL Limited Business Overview Table 109. CSL Limited Human Vaccine Contract Manufacturing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. CSL Limited Human Vaccine Contract Manufacturing Product Portfolio Table 111. CSL Limited Recent Development Table 112. BioNTech SE Company Information Table 113. BioNTech SE Business Overview Table 114. BioNTech SE Human Vaccine Contract Manufacturing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. BioNTech SE Human Vaccine Contract Manufacturing Product Portfolio Table 116. BioNTech SE Recent Development Table 117. Wuxi Biologics Company Information Table 118. Wuxi Biologics Business Overview Table 119. Wuxi Biologics Human Vaccine Contract Manufacturing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. Wuxi Biologics Human Vaccine Contract Manufacturing Product Portfolio Table 121. Wuxi Biologics Recent Development Table 122. Samsung Biologics Company Information Table 123. Samsung Biologics Business Overview Table 124. Samsung Biologics Human Vaccine Contract Manufacturing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. Samsung Biologics Human Vaccine Contract Manufacturing Product Portfolio Table 126. Samsung Biologics Recent Development Table 127. Boehringer Ingelheim Company Information Table 128. Boehringer Ingelheim Business Overview Table 129. Boehringer Ingelheim Human Vaccine Contract Manufacturing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 130. Boehringer Ingelheim Human Vaccine Contract Manufacturing Product Portfolio Table 131. Boehringer Ingelheim Recent Development Table 132. Novavax, Inc. Company Information Table 133. Novavax, Inc. Business Overview Table 134. Novavax, Inc. Human Vaccine Contract Manufacturing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 135. Novavax, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 136. Novavax, Inc. Recent Development Table 137. North America Human Vaccine Contract Manufacturing Revenue by Type (2021-2026) & (US$ Million) Table 138. North America Human Vaccine Contract Manufacturing Revenue by Type (2027-2032) & (US$ Million) Table 139. North America Human Vaccine Contract Manufacturing Revenue by Application (2021-2026) & (US$ Million) Table 140. North America Human Vaccine Contract Manufacturing Revenue by Application (2027-2032) & (US$ Million) Table 141. North America Human Vaccine Contract Manufacturing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. North America Human Vaccine Contract Manufacturing Revenue by Country (2021-2026) & (US$ Million) Table 143. North America Human Vaccine Contract Manufacturing Revenue by Country (US$ Million) & (2027-2032) Table 144. Europe Human Vaccine Contract Manufacturing Revenue by Type (2021-2026) & (US$ Million) Table 145. Europe Human Vaccine Contract Manufacturing Revenue by Type (2027-2032) & (US$ Million) Table 146. Europe Human Vaccine Contract Manufacturing Revenue by Application (2021-2026) & (US$ Million) Table 147. Europe Human Vaccine Contract Manufacturing Revenue by Application (2027-2032) & (US$ Million) Table 148. Europe Human Vaccine Contract Manufacturing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. Europe Human Vaccine Contract Manufacturing Revenue by Country (2021-2026) & (US$ Million) Table 150. Europe Human Vaccine Contract Manufacturing Revenue by Country (US$ Million) & (2027-2032) Table 151. China Human Vaccine Contract Manufacturing Revenue by Type (2021-2026) & (US$ Million) Table 152. China Human Vaccine Contract Manufacturing Revenue by Type (2027-2032) & (US$ Million) Table 153. China Human Vaccine Contract Manufacturing Revenue by Application (2021-2026) & (US$ Million) Table 154. China Human Vaccine Contract Manufacturing Revenue by Application (2027-2032) & (US$ Million) Table 155. Asia Human Vaccine Contract Manufacturing Revenue by Type (2021-2026) & (US$ Million) Table 156. Asia Human Vaccine Contract Manufacturing Revenue by Type (2027-2032) & (US$ Million) Table 157. Asia Human Vaccine Contract Manufacturing Revenue by Application (2021-2026) & (US$ Million) Table 158. Asia Human Vaccine Contract Manufacturing Revenue by Application (2027-2032) & (US$ Million) Table 159. Asia Human Vaccine Contract Manufacturing Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 160. Asia Human Vaccine Contract Manufacturing Revenue by Region (US$ Million) & (2021-2026) Table 161. Asia Human Vaccine Contract Manufacturing Revenue by Region (US$ Million) & (2027-2032) Table 162. SAMEA Human Vaccine Contract Manufacturing Revenue by Type (2021-2026) & (US$ Million) Table 163. SAMEA Human Vaccine Contract Manufacturing Revenue by Type (2027-2032) & (US$ Million) Table 164. SAMEA Human Vaccine Contract Manufacturing Revenue by Application (2021-2026) & (US$ Million) Table 165. SAMEA Human Vaccine Contract Manufacturing Revenue by Application (2027-2032) & (US$ Million) Table 166. SAMEA Human Vaccine Contract Manufacturing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 167. SAMEA Human Vaccine Contract Manufacturing Revenue by Country (2021-2026) & (US$ Million) Table 168. SAMEA Human Vaccine Contract Manufacturing Revenue by Country (US$ Million) & (2027-2032) Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. Human Vaccine Contract Manufacturing Image Figure 2. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Vaccine Contract Manufacturing Market Size Share 2021 VS 2025 VS 2032 Figure 4. Attenuated Image Figure 5. Inactivated Image Figure 6. Subunit-based Image Figure 7. Toxoid-based Image Figure 8. DNA-based Image Figure 9. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Human Vaccine Contract Manufacturing Market Size Share 2021 VS 2025 VS 2032 Figure 11. Downstream Image Figure 12. Upstream Image Figure 13. Global Human Vaccine Contract Manufacturing Market Size (US$ Million) & (2021-2032) Figure 14. Global Human Vaccine Contract Manufacturing Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Human Vaccine Contract Manufacturing Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Human Vaccine Contract Manufacturing Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Human Vaccine Contract Manufacturing Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Human Vaccine Contract Manufacturing Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Human Vaccine Contract Manufacturing Revenue Market Share by Type (2021-2032) Figure 21. Global Human Vaccine Contract Manufacturing Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Human Vaccine Contract Manufacturing Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Human Vaccine Contract Manufacturing Revenue Market Share by Application (2021-2032) Figure 24. North America Human Vaccine Contract Manufacturing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Human Vaccine Contract Manufacturing Revenue Share by Type (2021-2032) Figure 26. North America Human Vaccine Contract Manufacturing Revenue Share by Application (2021-2032) Figure 27. North America Human Vaccine Contract Manufacturing Revenue Share by Country (2021-2032) Figure 28. United States Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Human Vaccine Contract Manufacturing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Human Vaccine Contract Manufacturing Revenue Share by Type (2021-2032) Figure 33. Europe Human Vaccine Contract Manufacturing Revenue Share by Application (2021-2032) Figure 34. Europe Human Vaccine Contract Manufacturing Revenue Share by Country (2021-2032) Figure 35. Germany Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Human Vaccine Contract Manufacturing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Human Vaccine Contract Manufacturing Revenue Share by Type (2021-2032) Figure 45. China Human Vaccine Contract Manufacturing Revenue Share by Application (2021-2032) Figure 46. Asia Human Vaccine Contract Manufacturing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Human Vaccine Contract Manufacturing Revenue Share by Type (2021-2032) Figure 48. Asia Human Vaccine Contract Manufacturing Revenue Share by Application (2021-2032) Figure 49. Asia Human Vaccine Contract Manufacturing Revenue Share by Region (2021-2032) Figure 50. Japan Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Human Vaccine Contract Manufacturing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Human Vaccine Contract Manufacturing Revenue Share by Type (2021-2032) Figure 58. SAMEA Human Vaccine Contract Manufacturing Revenue Share by Application (2021-2032) Figure 59. SAMEA Human Vaccine Contract Manufacturing Revenue Share by Country (2021-2032) Figure 60. Brazil Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Human Vaccine Contract Manufacturing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Attenuated
  • Inactivated
  • Subunit-based
  • Toxoid-based
  • DNA-based
Applications
  • Downstream
  • Upstream
Companies covered
  • Lonza
  • Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • Ajinomoto Althea, Inc.
  • Merck KgaA
  • Cytovance Biologics
  • Catalent, Inc.
  • IDT Biologika GmbH
  • Albany Molecular Research, Inc.
  • PRA Health Sciences
  • ICON plc.
  • Pharmaceutical Product Development, LLC
  • Cobra Bio
  • Paragon Bioservices, Inc.
  • Emergent BioSolutions Inc.
  • CSL Limited
  • BioNTech SE
  • Wuxi Biologics
  • Samsung Biologics
  • Boehringer Ingelheim
  • Novavax, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Human Vaccine Contract Manufacturing Market by Type
  3. 1.2.1 Global Human Vaccine Contract Manufacturing Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Attenuated
  5. 1.2.3 Inactivated
  6. 1.2.4 Subunit-based
  7. 1.2.5 Toxoid-based
  8. 1.2.6 DNA-based
  9. 1.3 Human Vaccine Contract Manufacturing Market by Application
  10. 1.3.1 Global Human Vaccine Contract Manufacturing Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Downstream
  12. 1.3.3 Upstream
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Human Vaccine Contract Manufacturing Market Dynamics
  1. 2.1 Human Vaccine Contract Manufacturing Industry Trends
  2. 2.2 Human Vaccine Contract Manufacturing Industry Drivers
  3. 2.3 Human Vaccine Contract Manufacturing Industry Opportunities and Challenges
  4. 2.4 Human Vaccine Contract Manufacturing Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Human Vaccine Contract Manufacturing Market Perspective (2021-2032)
  2. 3.2 Global Human Vaccine Contract Manufacturing Growth Trends by Region
  3. 3.2.1 Global Human Vaccine Contract Manufacturing Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Human Vaccine Contract Manufacturing Market Size by Region (2021-2026)
  5. 3.2.3 Global Human Vaccine Contract Manufacturing Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Human Vaccine Contract Manufacturing Revenue by Players
  2. 4.1.1 Global Human Vaccine Contract Manufacturing Revenue by Players (2021-2026)
  3. 4.1.2 Global Human Vaccine Contract Manufacturing Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Human Vaccine Contract Manufacturing Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Human Vaccine Contract Manufacturing Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Human Vaccine Contract Manufacturing Key Players Headquarters & Area Served
  7. 4.4 Global Human Vaccine Contract Manufacturing Players, Product Type & Application
  8. 4.5 Global Human Vaccine Contract Manufacturing Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Human Vaccine Contract Manufacturing Market CR5 and HHI
  11. 4.6.3 2025 Human Vaccine Contract Manufacturing Tier 1, Tier 2, and Tier 3
5 Human Vaccine Contract Manufacturing Market Size by Type
  1. 5.1 Global Human Vaccine Contract Manufacturing Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Human Vaccine Contract Manufacturing Revenue by Type (2021-2032)
  3. 5.3 Global Human Vaccine Contract Manufacturing Revenue Market Share by Type (2021-2032)
6 Human Vaccine Contract Manufacturing Market Size by Application
  1. 6.1 Global Human Vaccine Contract Manufacturing Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Human Vaccine Contract Manufacturing Revenue by Application (2021-2032)
  3. 6.3 Global Human Vaccine Contract Manufacturing Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Lonza
  2. 7.1.1 Lonza Company Information
  3. 7.1.2 Lonza Business Overview
  4. 7.1.3 Lonza Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Lonza Human Vaccine Contract Manufacturing Product Portfolio
  6. 7.1.5 Lonza Recent Developments
  7. 7.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  8. 7.2.1 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Company Information
  9. 7.2.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Business Overview
  10. 7.2.3 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product Portfolio
  12. 7.2.5 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Developments
  13. 7.3 Ajinomoto Althea, Inc.
  14. 7.3.1 Ajinomoto Althea, Inc. Company Information
  15. 7.3.2 Ajinomoto Althea, Inc. Business Overview
  16. 7.3.3 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  18. 7.3.5 Ajinomoto Althea, Inc. Recent Developments
  19. 7.4 Merck KgaA
  20. 7.4.1 Merck KgaA Company Information
  21. 7.4.2 Merck KgaA Business Overview
  22. 7.4.3 Merck KgaA Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Merck KgaA Human Vaccine Contract Manufacturing Product Portfolio
  24. 7.4.5 Merck KgaA Recent Developments
  25. 7.5 Cytovance Biologics
  26. 7.5.1 Cytovance Biologics Company Information
  27. 7.5.2 Cytovance Biologics Business Overview
  28. 7.5.3 Cytovance Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Cytovance Biologics Human Vaccine Contract Manufacturing Product Portfolio
  30. 7.5.5 Cytovance Biologics Recent Developments
  31. 7.6 Catalent, Inc.
  32. 7.6.1 Catalent, Inc. Company Information
  33. 7.6.2 Catalent, Inc. Business Overview
  34. 7.6.3 Catalent, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Catalent, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  36. 7.6.5 Catalent, Inc. Recent Developments
  37. 7.7 IDT Biologika GmbH
  38. 7.7.1 IDT Biologika GmbH Company Information
  39. 7.7.2 IDT Biologika GmbH Business Overview
  40. 7.7.3 IDT Biologika GmbH Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  41. 7.7.4 IDT Biologika GmbH Human Vaccine Contract Manufacturing Product Portfolio
  42. 7.7.5 IDT Biologika GmbH Recent Developments
  43. 7.8 Albany Molecular Research, Inc.
  44. 7.8.1 Albany Molecular Research, Inc. Company Information
  45. 7.8.2 Albany Molecular Research, Inc. Business Overview
  46. 7.8.3 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  48. 7.8.5 Albany Molecular Research, Inc. Recent Developments
  49. 7.9 PRA Health Sciences
  50. 7.9.1 PRA Health Sciences Company Information
  51. 7.9.2 PRA Health Sciences Business Overview
  52. 7.9.3 PRA Health Sciences Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  53. 7.9.4 PRA Health Sciences Human Vaccine Contract Manufacturing Product Portfolio
  54. 7.9.5 PRA Health Sciences Recent Developments
  55. 7.10 ICON plc.
  56. 7.10.1 ICON plc. Company Information
  57. 7.10.2 ICON plc. Business Overview
  58. 7.10.3 ICON plc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  59. 7.10.4 ICON plc. Human Vaccine Contract Manufacturing Product Portfolio
  60. 7.10.5 ICON plc. Recent Developments
  61. 7.11 Pharmaceutical Product Development, LLC
  62. 7.11.1 Pharmaceutical Product Development, LLC Company Information
  63. 7.11.2 Pharmaceutical Product Development, LLC Business Overview
  64. 7.11.3 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product Portfolio
  66. 7.11.5 Pharmaceutical Product Development, LLC Recent Developments
  67. 7.12 Cobra Bio
  68. 7.12.1 Cobra Bio Company Information
  69. 7.12.2 Cobra Bio Business Overview
  70. 7.12.3 Cobra Bio Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Cobra Bio Human Vaccine Contract Manufacturing Product Portfolio
  72. 7.12.5 Cobra Bio Recent Developments
  73. 7.13 Paragon Bioservices, Inc.
  74. 7.13.1 Paragon Bioservices, Inc. Company Information
  75. 7.13.2 Paragon Bioservices, Inc. Business Overview
  76. 7.13.3 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  78. 7.13.5 Paragon Bioservices, Inc. Recent Developments
  79. 7.14 Emergent BioSolutions Inc.
  80. 7.14.1 Emergent BioSolutions Inc. Company Information
  81. 7.14.2 Emergent BioSolutions Inc. Business Overview
  82. 7.14.3 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product Portfolio
  84. 7.14.5 Emergent BioSolutions Inc. Recent Developments
  85. 7.15 CSL Limited
  86. 7.15.1 CSL Limited Company Information
  87. 7.15.2 CSL Limited Business Overview
  88. 7.15.3 CSL Limited Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  89. 7.15.4 CSL Limited Human Vaccine Contract Manufacturing Product Portfolio
  90. 7.15.5 CSL Limited Recent Developments
  91. 7.16 BioNTech SE
  92. 7.16.1 BioNTech SE Company Information
  93. 7.16.2 BioNTech SE Business Overview
  94. 7.16.3 BioNTech SE Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  95. 7.16.4 BioNTech SE Human Vaccine Contract Manufacturing Product Portfolio
  96. 7.16.5 BioNTech SE Recent Developments
  97. 7.17 Wuxi Biologics
  98. 7.17.1 Wuxi Biologics Company Information
  99. 7.17.2 Wuxi Biologics Business Overview
  100. 7.17.3 Wuxi Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Wuxi Biologics Human Vaccine Contract Manufacturing Product Portfolio
  102. 7.17.5 Wuxi Biologics Recent Developments
  103. 7.18 Samsung Biologics
  104. 7.18.1 Samsung Biologics Company Information
  105. 7.18.2 Samsung Biologics Business Overview
  106. 7.18.3 Samsung Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Samsung Biologics Human Vaccine Contract Manufacturing Product Portfolio
  108. 7.18.5 Samsung Biologics Recent Developments
  109. 7.19 Boehringer Ingelheim
  110. 7.19.1 Boehringer Ingelheim Company Information
  111. 7.19.2 Boehringer Ingelheim Business Overview
  112. 7.19.3 Boehringer Ingelheim Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Boehringer Ingelheim Human Vaccine Contract Manufacturing Product Portfolio
  114. 7.19.5 Boehringer Ingelheim Recent Developments
  115. 7.20 Novavax, Inc.
  116. 7.20.1 Novavax, Inc. Company Information
  117. 7.20.2 Novavax, Inc. Business Overview
  118. 7.20.3 Novavax, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Novavax, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  120. 7.20.5 Novavax, Inc. Recent Developments
8 North America
  1. 8.1 North America Human Vaccine Contract Manufacturing Revenue (2021-2032)
  2. 8.2 North America Human Vaccine Contract Manufacturing Revenue by Type (2021-2032)
  3. 8.2.1 North America Human Vaccine Contract Manufacturing Revenue by Type (2021-2026)
  4. 8.2.2 North America Human Vaccine Contract Manufacturing Revenue by Type (2027-2032)
  5. 8.3 North America Human Vaccine Contract Manufacturing Revenue Share by Type (2021-2032)
  6. 8.4 North America Human Vaccine Contract Manufacturing Revenue by Application (2021-2032)
  7. 8.4.1 North America Human Vaccine Contract Manufacturing Revenue by Application (2021-2026)
  8. 8.4.2 North America Human Vaccine Contract Manufacturing Revenue by Application (2027-2032)
  9. 8.5 North America Human Vaccine Contract Manufacturing Revenue Share by Application (2021-2032)
  10. 8.6 North America Human Vaccine Contract Manufacturing Revenue by Country
  11. 8.6.1 North America Human Vaccine Contract Manufacturing Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Human Vaccine Contract Manufacturing Revenue by Country (2021-2026)
  13. 8.6.3 North America Human Vaccine Contract Manufacturing Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Human Vaccine Contract Manufacturing Revenue (2021-2032)
  2. 9.2 Europe Human Vaccine Contract Manufacturing Revenue by Type (2021-2032)
  3. 9.2.1 Europe Human Vaccine Contract Manufacturing Revenue by Type (2021-2026)
  4. 9.2.2 Europe Human Vaccine Contract Manufacturing Revenue by Type (2027-2032)
  5. 9.3 Europe Human Vaccine Contract Manufacturing Revenue Share by Type (2021-2032)
  6. 9.4 Europe Human Vaccine Contract Manufacturing Revenue by Application (2021-2032)
  7. 9.4.1 Europe Human Vaccine Contract Manufacturing Revenue by Application (2021-2026)
  8. 9.4.2 Europe Human Vaccine Contract Manufacturing Revenue by Application (2027-2032)
  9. 9.5 Europe Human Vaccine Contract Manufacturing Revenue Share by Application (2021-2032)
  10. 9.6 Europe Human Vaccine Contract Manufacturing Revenue by Country
  11. 9.6.1 Europe Human Vaccine Contract Manufacturing Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Human Vaccine Contract Manufacturing Revenue by Country (2021-2026)
  13. 9.6.3 Europe Human Vaccine Contract Manufacturing Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Human Vaccine Contract Manufacturing Revenue (2021-2032)
  2. 10.2 China Human Vaccine Contract Manufacturing Revenue by Type (2021-2032)
  3. 10.2.1 China Human Vaccine Contract Manufacturing Revenue by Type (2021-2026)
  4. 10.2.2 China Human Vaccine Contract Manufacturing Revenue by Type (2027-2032)
  5. 10.3 China Human Vaccine Contract Manufacturing Revenue Share by Type (2021-2032)
  6. 10.4 China Human Vaccine Contract Manufacturing Revenue by Application (2021-2032)
  7. 10.4.1 China Human Vaccine Contract Manufacturing Revenue by Application (2021-2026)
  8. 10.4.2 China Human Vaccine Contract Manufacturing Revenue by Application (2027-2032)
  9. 10.5 China Human Vaccine Contract Manufacturing Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Human Vaccine Contract Manufacturing Revenue (2021-2032)
  2. 11.2 Asia Human Vaccine Contract Manufacturing Revenue by Type (2021-2032)
  3. 11.2.1 Asia Human Vaccine Contract Manufacturing Revenue by Type (2021-2026)
  4. 11.2.2 Asia Human Vaccine Contract Manufacturing Revenue by Type (2027-2032)
  5. 11.3 Asia Human Vaccine Contract Manufacturing Revenue Share by Type (2021-2032)
  6. 11.4 Asia Human Vaccine Contract Manufacturing Revenue by Application (2021-2032)
  7. 11.4.1 Asia Human Vaccine Contract Manufacturing Revenue by Application (2021-2026)
  8. 11.4.2 Asia Human Vaccine Contract Manufacturing Revenue by Application (2027-2032)
  9. 11.5 Asia Human Vaccine Contract Manufacturing Revenue Share by Application (2021-2032)
  10. 11.6 Asia Human Vaccine Contract Manufacturing Revenue by Country
  11. 11.6.1 Asia Human Vaccine Contract Manufacturing Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Human Vaccine Contract Manufacturing Revenue by Country (2021-2026)
  13. 11.6.3 Asia Human Vaccine Contract Manufacturing Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Human Vaccine Contract Manufacturing Revenue (2021-2032)
  2. 12.2 SAMEA Human Vaccine Contract Manufacturing Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Human Vaccine Contract Manufacturing Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Human Vaccine Contract Manufacturing Revenue by Type (2027-2032)
  5. 12.3 SAMEA Human Vaccine Contract Manufacturing Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Human Vaccine Contract Manufacturing Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Human Vaccine Contract Manufacturing Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Human Vaccine Contract Manufacturing Revenue by Application (2027-2032)
  9. 12.5 SAMEA Human Vaccine Contract Manufacturing Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Human Vaccine Contract Manufacturing Revenue by Country
  11. 12.6.1 SAMEA Human Vaccine Contract Manufacturing Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Human Vaccine Contract Manufacturing Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Human Vaccine Contract Manufacturing Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst